ArticleJournal of pharmacy & bioallied sciences2025
Managing Burning Mouth Syndrome with Omega-3 Fatty Acids: A Clinical Trial of Pain Relief and Quality of Life Improvement.
Article in Journal of pharmacy & bioallied sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: An inexplicable burning sensation in the oral mucosa is the hallmark of Burning Mouth Syndrome (BMS), a chronic illness that is often connected to inflammatory and neuropathic processes. Materials and Methods: A double-blind, randomized, placebo-controlled study including 120 individuals with a BMS diagnosis was carried out. Over the course of 12 weeks, participants were randomized to receive either a placebo or 2 grams of omega-3 fatty acids (EPA and DHA) daily. The Visual Analog Scale (VAS) was used to quantify the change in pain intensity, which was the main result. Secondary outcomes were patient-reported symptom alleviation and quality of life as measured by the Oral Health Impact Profile (OHIP-14). Results: In total, 110 out of the 120 individuals finished the study. When compared to the placebo group, the omega-3 group's VAS pain ratings significantly decreased (mean change: -3.4 vs. -1.2, Conclusion: Omega-3 fatty acid supplementation significantly reduces pain and improves quality of life in patients with BMS, providing a safe and effective alternative to conventional treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.